Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A randomized controlled trial comparing the efficacy and safety of two HMG preparations gaining their LH bioactivity from different HCG sources

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meditation and mindfulness reduce perceived stress in women with recurrent pregnancy loss: a randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Stress and depression among women and men who have experienced recurrent pregnancy loss: focusing on both sexes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Empathetic application of machine learning may address appropriate utilization of ART

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Futures and fears in the freezer: Danish women's experiences with ovarian tissue cryopreservation and transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The reproductive microbiome - clinical practice recommendations for fertility specialists

    Research output: Contribution to journalReviewResearchpeer-review

  • Gillian Lockwood
  • Barbara Cometti
  • Jeanette Bogstad
  • Karin Erb
  • Christian De Geyter
  • Janos Urbancsek
  • Silvia Trevisan
  • Khaled Pocate-Cheriet
  • Dominique de Ziegler
View graph of relations

In this prospective, controlled, randomized, multicentre, non-inferiority study, efficacy and safety of two HMG preparations (Menopur(®)- Ferring and Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI 30 kg/m(2) or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid toovarian hyperstimulation syndrome (OHSS). No statistically significant differences between the treatment groups were reported for most of the clinically significant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the difference equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent. The safety profile of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG preparation is a viable alternative for conducting ovarian stimulation in IVF cycles.

Original languageEnglish
JournalReproductive BioMedicine Online
Volume35
Issue number1
Pages (from-to)17-27
ISSN1472-6483
DOIs
Publication statusPublished - 1 Jul 2017

    Research areas

  • Journal Article

ID: 50560266